MANGOCEUTICALS, INC.MGRXEarnings & Financial Report
MANGOCEUTICALS, INC. is a men's health and personal care company that develops, manufactures, and distributes science-backed consumer products, including dietary supplements, skincare, and hair care solutions targeted at common male wellness needs. It mainly operates in the U.S. market, selling via direct-to-consumer e-commerce platforms and select retail partners, prioritizing accessible, transparent wellness offerings for adult male consumers.
MGRX Q4 FY2025 Key Financial Metrics
Revenue
$94.4K
Gross Profit
$47.5K
Operating Profit
$-367.7K
Net Profit
$-2.8M
Gross Margin
50.3%
Operating Margin
-389.7%
Net Margin
-2935.1%
YoY Growth
-10.3%
EPS
$0.38
MANGOCEUTICALS, INC. Q4 FY2025 Financial Summary
MANGOCEUTICALS, INC. reported revenue of $94.4K (down 10.3% YoY) for Q4 FY2025, with a net profit of $-2.8M (down 42.1% YoY) (-2935.1% margin). Cost of goods sold was $46.9K, operating expenses totaled $415.2K.
Key Financial Metrics
| Total Revenue | $94.4K |
|---|---|
| Net Profit | $-2.8M |
| Gross Margin | 50.3% |
| Operating Margin | -389.7% |
| Report Period | Q4 FY2025 |
MANGOCEUTICALS, INC. Annual Revenue by Year
MANGOCEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $456.0K).
MANGOCEUTICALS, INC. Quarterly Revenue & Net Profit History
MANGOCEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $94.4K | -10.3% | $-2.8M | -2935.1% |
| Q3 FY2025 | $84.2K | -36.8% | $-7.6M | -9042.8% |
| Q2 FY2025 | $168.1K | +3.0% | $-5.4M | -3221.6% |
| Q1 FY2025 | $109.3K | -48.9% | $-4.8M | -4427.4% |
| Q4 FY2024 | $105.2K | -56.9% | $-1.9M | -1851.2% |
| Q3 FY2024 | $133.4K | -45.6% | $-2.0M | -1499.0% |
| Q2 FY2024 | $163.2K | +15.5% | $-2.4M | -1465.4% |
| Q1 FY2024 | $214.1K | +112.6% | $-2.4M | -1105.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $214095 | $163163 | $133368 | $105247 | $109306 | $168109 | $84246 | $94360 |
| YoY Growth | 112.6% | 15.5% | -45.6% | -56.9% | -48.9% | 3.0% | -36.8% | -10.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $301447 | $15.2M | $14.8M | $15.4M | $21.8M | $20.8M | $16.5M | $16.1M |
| Liabilities | $1.3M | $1.4M | $1.4M | $1.4M | $1.5M | $1.6M | $804275 | $890568 |
| Equity | $-958432 | $13.8M | $13.4M | $13.9M | $20.3M | $19.2M | $15.7M | $15.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-991131 | $-1.6M | $-1.2M | $-1.1M | $-2.3M | $-1.3M | $-1.2M | $-1.1M |